Latest News

A selection of recent news and views from Catapult Ventures follows...

Breakthrough in identifying risk of renal impairment in people with diabetes

Research published in the Future of Healthcare Journal shows that models developed by UK healthtech start-up Gendius can determine which patients with type 2 diabetes are most likely to have renal impairment, allowing healthcare systems to priorit...

INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project

Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation o...

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme

Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive d...

MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry

A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant le...

iiCON to expand pipeline following Research England funding boost

The outstanding results being achieved by the Infection Innovation Consortium – iiCON – have been acknowledged today, with £1.7 million of additional funding from Research England confirmed. Led by Liverpool School of Tropical M...

From our portfolio

Blueberry Therapeutics


Blueberry Therapeutics is a biotechnology company developing a range of anti-microbial products u...

viewview our portfolio

Our Team

Dr Gareth King

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200